← Back to Search
Monoclonal Antibodies
BMS-986489 vs Atezolizumab for Small Cell Lung Cancer
Orange City, FL
Phase 3
Recruiting
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system
Must not have
Participants have already received certain types of treatment for extensive stage small cell lung cancer
Participants have certain health conditions such as spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Pivotal Trial
Summary
This trial aims to compare the effectiveness and safety of a combination treatment (BMS-986489 with Carboplatin plus Etoposide) to another combination treatment (Atezolizum
See full description
Who is the study for?
This trial is for individuals with extensive-stage small cell lung cancer who are receiving their first line of therapy. Specific eligibility criteria details were not provided, so interested participants should inquire further to determine if they meet the necessary requirements.Check my eligibility
What is being tested?
The study aims to compare a new treatment combination (BMS-986489, which includes Anti-fucosyl-GM1 and Nivolumab) with Carboplatin and Etoposide against an existing treatment (Atezolizumab) with the same chemotherapy drugs in patients with extensive-stage small cell lung cancer.See study design
What are the potential side effects?
Potential side effects may include immune-related reactions due to Nivolumab or Atezolizumab, such as inflammation in organs, infusion reactions; chemotherapy-related issues like nausea, fatigue, hair loss; specific side effect profiles for BMS-986489 are not detailed here.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with extensive-stage small cell lung cancer.
show original
Select...
I have a tumor outside the brain that can be measured by CT or MRI.
show original
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have received treatments for advanced small cell lung cancer.
show original
Select...
I have health issues like brain cancer spread, lung/heart disease, infections, other cancers, or nerve damage.
show original
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm AExperimental Treatment3 Interventions
Group II: Arm BActive Control3 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboplatin
2014
Completed Phase 3
~6450
Etoposide
2010
Completed Phase 3
~2970
Find a Location
Closest Location:Local Institution - 0009· Orange City, FL
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,724 Previous Clinical Trials
4,127,947 Total Patients Enrolled